FDA Brief

Warning letters Drugs

FDA warning letter to

New York State Psychiatric Institute IRB

High riskIssued Mar 21, 2024Posted Mar 26, 2024Center for Drug Evaluation and Research | CDER

FDA warned New York State Psychiatric Institute's review board it failed to report serious research problems and reviewed drug studies without required nonscientific member.

What happened

FDA inspected the New York State Psychiatric Institute Institutional Review Board from January 23 to February 2, 2023, as part of its bioresearch monitoring program. FDA found the IRB did not follow its written procedures for promptly reporting unanticipated problems, serious or continuing noncompliance, and suspension of IRB approval to FDA. FDA also found that on June 17, 2019, the IRB reviewed and approved FDA-regulated research at a convened meeting without at least one member whose primary concerns were in nonscientific areas.

What FDA found

  1. The IRB did not prepare, maintain, or follow written procedures for promptly reporting unanticipated problems, serious or continuing noncompliance, and suspension or termination of IRB approval to FDA and institutional officials.

    21 CFR 56.108(b); 21 CFR 56.115(a)(6); 21 CFR 56.113
  2. The IRB did not report to FDA an unanticipated problem involving risk to subjects after it determined that a subject's death by suicide was such a problem on August 9, 2021.

    21 CFR 56.108(b)
  3. The IRB did not promptly report to FDA serious or continuing noncompliance by investigators for three clinical studies, despite determining or discussing such noncompliance at meetings in 2021 and 2022.

    21 CFR 56.108(b)
  4. The IRB did not report to FDA its July 11, 2022, suspension of IRB approval for research under a protocol.

    21 CFR 56.113; 21 CFR 56.108(b)
  5. The IRB reviewed and approved FDA-regulated research at a June 17, 2019, convened meeting without at least one member whose primary concerns were in nonscientific areas present.

    21 CFR 56.108(c)

What FDA wants

Within 15 business days, FDA asks the IRB to respond in writing with corrective actions, training records or a training timeline, and revised or draft written procedures and policies with an implementation timeline. FDA also asks for corrective or preventive actions to ensure a nonscientific member is present when FDA-regulated research is reviewed.

Who should pay attention

  • IRBs reviewing FDA-regulated drug studies
  • research institutions and sponsors relying on this IRB
  • clinical trial sponsors and contract research organizations using NYSPI IRB

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd.

    FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.

    High risk
  2. Adnan Dahdul, MD

    FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.

    High risk
  3. Naseem A. Jaffrani, M.D.

    FDA says clinical investigator Dr. Naseem Jaffrani failed to report serious adverse events to sponsors within 24 hours in two drug trials.

    High risk
  4. Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre

    FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.

    High risk